ROIV

ROIV

Roivant Sciences Ltd

Net 11.18%top 1%Rev -8.81%top 1%Net income grew 100% of years1Y
Hold

Roivant Sciences Ltd. develops and commercializes medicines and technologies, focusing on clinical-stage biopharmaceuticals. Its candidates include monoclonal antibodies for autoimmune diseases and small molecule inhibitors for immune-mediated conditions.

βš•οΈ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago β†’$3,638today

Score Overview

1 Year
Scoreβ€”
Net Growth11.18%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth-8.81%
Rev TrendShrank
Revenue Consistencyβ€”
All Time
Scoreβ€”
Net Growth68.50%
Net Trend40%
Net Income Consistency
Rev Growth-86.38%
Rev Trend20%
Revenue Consistency

See the full market ranking β†’

Roivant Sciences Ltd fundamental performance

Across Roivant Sciences Ltd's full reported history, from 2022 to 2026, revenue declined from $ 55M to $ 8M and net income went from -$ 845M to -$ 299M. Revenue increased in 20% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 36.16β€”
1 Year2025-08-12
$ 11.57212.53%
5 Years2021-08-12
$ 9.94263.78%
All Time2021-10-01
$ 9.35286.74%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2027$ 7M-$ 266M$ 3.84B
2026$ 8M-$ 299M$ 4.29B
2025$ 29M-$ 171M$ 4.88B
2024$ 32M$ 4.34B$ 6.54B
2023$ 31M-$ 1.00B$ 1.68B
2022$ 55M-$ 845M$ 2.06B

Explore beyond ROIV

You're looking at Roivant Sciences Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies